BIO
Biome Australia Limited
🇦🇺 ASX
🛍️ CONSUMER
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 53.35%
Annual Growth
3 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
26
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Biome Australia Ltd. engages in the research, development, manufacture, and distribution of evidence-based products linking the gut and human health. The firm develops, licenses, commercializes and markets evidence-based live biotherapeutics (probiotics) and complementary medicines. The company develops, manufactures, and distributes evidence-based products linking the gut and human health through the Company owned brands, such as Activated Nutrients and Activated Probiotics. Activated Nutrients offers a range of completely organic, plant-based, all in-one nutritional products. Activated Probiotics offers a range of clinically backed precision probiotics. Activated Probiotics provides live biotherapeutic products clinically proven to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema through randomized double-blind placebo-controlled trials. Activated Probiotics products include Biome Acne Probiotic, Biome Baby Probiotic, Biome Eczema Probiotic, and Biome Acne Probiotic.
📈 Performance
Price History
+175.00%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.55
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in BIO
26
📊 Total Capital Earnings
$5K
🔃 Average investment frequency
31 weeks
💵 Average investment amount
$1,465
⏰ Last time a customer invested in BIO
56 mins
BIO investor breakdown
💵 Income of investors
More than 200k
10%
150k - 200k
100k - 150k
50k - 100k
47%
Less than 50k
33%
👶 Age of investors
18 - 25
19%
26 - 34
19%
35 - 90
62%
🙋 Legal gender of investors
Female
50%
Male
50%
Pearlers who invest in BIO also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
6.14%
📊 Share price
$99.21 AUD
🧱 MATERIALS
💸 FINANCIALS
⛳️ DIVERSIFIED
🇦🇺 AUSTRALIA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
16.56%
📊 Share price
$137.98 AUD
🤖 TECHNOLOGY
🌏 GLOBAL
📈 HIGH PRICE GROWTH
⛳️ DIVERSIFIED
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
21.91%
📊 Share price
$60.71 AUD
🇺🇸 UNITED STATES
📈 HIGH PRICE GROWTH
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The company develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. The company operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. The company operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.
🙌 Performance (5Yr p.a)
457.24%
📊 Share price
$27.68 AUD
🧬 BIOTECHNOLOGY
Commonwealth Bank of Australia engages in the provision of banking and financial services. The company is headquartered in Sydney, New South Wales and currently employs 48,887 full-time employees. The company serves approximately 17 million customers. The firm's segments include Retail Banking Services, Business Banking, Institutional Banking and Markets and New Zealand. Retail Banking Services segment provides banking products and services to personal customers, and banking and advisory services for high-net-worth individuals. Business Banking serves the banking needs of business, corporate and agribusiness customers across the full range of financial service solutions. Institutional Banking and Markets offers a full range of financial services solutions including access to debt capital markets, transaction banking, working capital and risk management. New Zealand includes the banking and funds management businesses operating in New Zealand under the ASB brand.
🙌 Performance (5Yr p.a)
20.38%
📊 Share price
$148.14 AUD
🏦 BANKING
⚖️ HIGH GOVERNANCE
🍃 HIGH ESG SCORE
📈 HIGH PRICE GROWTH
🌳 ENVIRONMENTAL
Want more shares? Try these...
